Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

about

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

Item

http://www.wikidata.org/entity/Q38812270

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Follicular lymphoma: in vitro ...... cytotoxicity (ADCC) activity.

@en

type

Item

label

Follicular lymphoma: in vitro ...... cytotoxicity (ADCC) activity.

@en

prefLabel

Follicular lymphoma: in vitro ...... cytotoxicity (ADCC) activity.

@en

P1476

Follicular lymphoma: in vitro ...... cytotoxicity (ADCC) activity.

@en

P2093

Angel Panizo

http://www.w3.org/2001/XMLSchema#string

Ascensión López-Díaz-de-Cerio

http://www.w3.org/2001/XMLSchema#string

Carlos Grande

http://www.w3.org/2001/XMLSchema#string

Carlos Panizo

http://www.w3.org/2001/XMLSchema#string

Esther Pena

http://www.w3.org/2001/XMLSchema#string

Jesus Feliu

http://www.w3.org/2001/XMLSchema#string

Mayte Olave

http://www.w3.org/2001/XMLSchema#string

Mercedes Rodríguez-Calvillo

http://www.w3.org/2001/XMLSchema#string

Pilar Giraldo

http://www.w3.org/2001/XMLSchema#string

Ricardo García-Muñoz

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching

Immunological aspects in chronic lymphocytic leukemia (CLL) development

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Effector memory T cells, early metastasis, and survival in colorectal cancer.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study

P2888

s12026-015-8747-9

P304

548-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12026-015-8747-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286652585

http://www.w3.org/2001/XMLSchema#string

P6179

1000858841

http://www.w3.org/2001/XMLSchema#string

P698

26659089

http://www.w3.org/2001/XMLSchema#string